ArticleBMC psychiatry2026
Gut-brain axis: biological correlations between inflammatory bowel disease and anxiety or depressive disorders - a scoping review of reviews.
Article in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The aryl hydrocarbon receptor and kynurenine pathway: connecting inflammatory bowel disease and depression via the microbiota gut brain axis.Frontiers in neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe bidirectional communication between the nervous system and the gastrointestinal tract plays a crucial role in maintaining homeostatic balance.The present study aims to understand the gut-brain axis and how this complex interaction relates to inflammatory bowel disease and the development of anxious and depressive symptoms.
methodThe search for articles was conducted in the MEDLINE, LILACS, and Cochrane databases. Reviews published between 2009 and 2025 that addressed the gut-brain interaction with a focus on the development of inflammatory bowel disease (IBD) and anxious and/or depressive signs were included. Incomplete studies and those that addressed only one aspect were not selected.
resultsThe search resulted in 87 studies; after four selection stages, 15 articles remained according to the inclusion and exclusion criteria. The highest number of publications was from the period of 2021 to 2024. The level of evidence collected consistently reported that patients with IBD were more likely to develop depressive and/or anxiety symptoms. Studies further indicate that inflammatory markers, including C-reactive protein (CRP), explain a large part of the risk for psychiatric conditions.
conclusionThe gut-brain axis should be understood as a potential factor in the development of mood disorders (anxiety and depression) in patients with IBD, due to the shared dysbiotic and immunological characteristics. By providing a comprehensive view of this complex bidirectional interconnection, the clinical significance of this association is reiterated, as well as the urgency to deepen the understanding of its pathophysiology. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.